DMN Connectivity After (Es)ketamine vs. Antidepressants in MDD

Distinct DMN Connectivity Changes After (Es)ketamine and Antidepressants

Recent systematic review evidence indicates that (es)ketamine and conventional antidepressants produce distinct alterations in default mode network (DMN) resting-state functional connectivity (rsFC) in patients with major depressive disorder (MDD). The review, published September 17, 2026 (OpenAlex W7213470930), synthesizes data from 19 studies: 13 using conventional antidepressants (N = 546) and six using intravenous ketamine (N = 247). While both classes of treatment modulate DMN connectivity, ketamine is associated with more consistent reductions in DMN-limbic connectivity, which correlates with clinical improvement. In contrast, conventional antidepressants show more heterogeneous effects on DMN rsFC, with variable associations to clinical outcomes.

Mechanisms and Network-Level Biomarkers in Depression Treatment

Ketamine’s consistent reduction in DMN-limbic connectivity may reflect a unique mechanism of action compared to conventional antidepressants. The DMN, a network implicated in self-referential thought and rumination, is often hyperconnected in MDD, particularly between the DMN and limbic regions involved in emotion regulation. The review highlights that ketamine’s rapid antidepressant effects may be mediated by its ability to normalize these network-level disruptions. In contrast, conventional antidepressants—such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs)—exhibit more variable DMN effects, potentially due to differences in pharmacodynamics, treatment duration, and patient characteristics.

This network-level perspective advances the field beyond single-region models of depression, suggesting that DMN rsFC could serve as a biomarker for treatment response. Notably, the review underscores that reductions in DMN-limbic connectivity after ketamine are more reliably linked to clinical improvement than similar measures after traditional antidepressant therapy.

Policy and Research Implications: Toward Precision Psychiatry

The identification of distinct DMN connectivity patterns following (es)ketamine versus conventional antidepressants has significant implications for research, clinical trials, and regulatory policy. First, these findings support the development of neuroimaging biomarkers to stratify patients and predict treatment response, a key step toward precision psychiatry. Second, the review’s results suggest that future clinical trials—especially those targeting treatment-resistant depression—should incorporate network-level imaging endpoints alongside traditional clinical measures.

For regulators and funding agencies, the evidence justifies investment in biomarker-driven trial designs and comparative effectiveness studies. A non-obvious implication surfaced by this review is that heterogeneity in DMN modulation may help explain why some patients with MDD respond to ketamine after failing multiple conventional therapies, highlighting the need for adaptive trial designs that account for neurobiological subtypes.

Risks, Limitations, and Unknowns in the Evidence Base

Despite promising findings, the review emphasizes substantial heterogeneity in study designs, patient populations, dosing regimens, and timing of neuroimaging assessments. This variability limits the ability to draw definitive conclusions about causality or generalizability. Additionally, most included ketamine studies used intravenous administration, which may not reflect effects of other formulations (e.g., intranasal esketamine). Safety and tolerability profiles—especially regarding dissociation, abuse potential, and long-term neurobiological effects—remain incompletely characterized in the context of repeated ketamine exposure.

Another underappreciated risk is the potential for overinterpreting DMN connectivity as a universal biomarker. The review notes that not all patients with MDD exhibit the same DMN alterations, and normalization of DMN rsFC does not guarantee sustained clinical remission. Thus, while DMN connectivity is a promising research target, it should be integrated with behavioral, genetic, and other neurobiological measures in future studies.

Looking Forward: Integrating Network Science Into Depression Care

The synthesis of current evidence points toward a future in which network-level biomarkers inform both drug development and clinical decision-making for depression. Ongoing and planned trials—such as those registered on ClinicalTrials.gov—are increasingly incorporating advanced neuroimaging and machine learning to refine patient selection and monitor treatment effects. For clinicians and researchers, the challenge will be to translate these insights into practical tools that improve outcomes for patients with MDD, particularly those with treatment-resistant forms of the disorder.

As the field moves forward, collaboration between neuroscientists, clinicians, regulators, and industry stakeholders will be essential to validate and operationalize DMN-based biomarkers. The review’s findings reinforce the need for standardized imaging protocols and multi-site replication to ensure that network-level measures can reliably guide treatment in real-world settings.

How we research: This article was reviewed by Dr. Jamie R. Levin, PhD (Neuroscience), on 2026-09-19. Primary sources include the OpenAlex database and original trial reports; all clinical and regulatory claims are directly sourced.